Effects of 17α-ethinylestradiol treatment on serum components in intact and hypophysectomized male rats
Intact and HYPOX male rats were injected s.c. daily with EE (5 mg/kg) for 1 and 5 days. Control rats received the appropriate vehicle (VEH). Twenty four hours after the last injection, serum was extracted, and serum markers were measured as described under Materials and Methods. Data represent a mean ± S.D. from serum samples of at least five individual rats.
Serum Markers | Intact | HYPOX | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| VEH | 1 Day | 5 Days | VEH | 1 Day | 5 Days | |||||
| 7α-Hydroxy-4-cholesten-3-one (μg/l) | 146.25 ± 35.95 | 71.75 ± 43.9* | 30.8 ± 11.8* | 78.75 ± 42.13* | 61 ± 23.93* | 30 ± 20.18* | ||||
| Total bilirubin (μM) | 2.25 ± 0.50 | 3 ± 0.10* | 3.4 ± 0.55* | 9 ± 5.29* | 8 ± 2.16 | 4.75 ± 0.96 | ||||
| Cholesterol (mM) | 1.6 ± 0.01 | N.D. | N.D. | 2.78 ± 0.46* | 2.23 ± 0.21 | N.D. | ||||
| ALP (μkat/l) | 10.20 ± 2.78 | 14.63 ± 1.36* | 14.2 ± 2.89* | 5.70 ± 2.35* | 6.4 ± 1.17 | 4 ± 0.70 | ||||
| γGT (μkat/l) | 0.10 ± 0.06 | 0.10 ± 0.04 | N.D. | 0.20 ± 0.08* | 0.20 ± 0.06 | N.D. | ||||
| ALAT (μkat/l) | 0.76 ± 0.10 | 0.86 ± 0.11 | 0.54 ± 0.08* | 0.57 ± 0.16 | 0.69 ± 0.17 | 0.31 ± 0.12* | ||||
| AST (μkat/l) | 1.47 ± 0.28 | 1.15 ± 0.10 | 1.28 ± 0.25 | 2.20 ± 0.87 | 1.99 ± 0.73 | 1.09 ± 0.18* | ||||
N.D., not detected; ALP, alkaline phosphatase; γ-GT, γ-glutamyltransferase; ALAT, alanine aminotransferase.
** P < 0.05, for comparison with vehicle-treated HYPOX rats.
↵* P < 0.05, for comparison with vehicle-treated intact rats.